Li Chunmei, Wu Maoyuan, Zhang Wenwen, Jiang Xiaoling, Zhang Lixia, Wang Gangcheng, He Lianli
Department of Gynecology, The Third Affiliated Hospital of Zunyi Medical University (The First People's Hospital of Zunyi), Zunyi, Guizhou, China.
Department of Abdominal and Pelvic Tumor Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Front Oncol. 2024 Jul 24;14:1419710. doi: 10.3389/fonc.2024.1419710. eCollection 2024.
Large Cell Neuroendocrine Carcinoma (LCNEC) of the cervix is an extremely rare but highly aggressive type of cervical cancer and it requires multimodal therapy to improve their quality of life. At present, there are no established, standardized treatment protocols for managing large cell neuroendocrine carcinoma of the cervix. In this report, we present a case of a patient with cervical LCNEC, Who was a 39-year-old woman who presented with irregular vaginal bleeding accompanied by lower abdominal distension for over a month. Examination revealed a cauliflower-like cervical mass approximately 4cm in diameter, with the normal cervical architecture distorted and partially fused to the vaginal wall. Following further investigations, the stage assigned was IVB, and who was started on neoadjuvant chemotherapy with the TC (paclitaxel + carboplatin) regimen but during neoadjuvant chemotherapy, The patient developed a vaginal urinary leakage. Then, The patient underwent a comprehensive treatment regimen that included pelvic exenteration, urinary system reconstruction, pelvic floor reconstruction, and chemotherapy. Given the patient's positive immunohistochemistry for EGFR, the treatment was combined with the anti-angiogenic drug, bevacizumab. The patient achieved complete remission following the comprehensive treatment. Through this case to explore individualized treatment for cervical LCNEC.
宫颈大细胞神经内分泌癌（LCNEC）是一种极为罕见但侵袭性很强的宫颈癌类型，需要多模式治疗以提高患者生活质量。目前，尚无既定的、标准化的治疗方案来管理宫颈大细胞神经内分泌癌。在本报告中，我们介绍了一例宫颈LCNEC患者，该患者为一名39岁女性，出现不规则阴道出血并伴有下腹胀满一个多月。检查发现宫颈有一个直径约4厘米的菜花状肿物，宫颈正常结构扭曲，部分与阴道壁融合。进一步检查后，分期为IVB期，患者开始接受TC（紫杉醇+卡铂）方案的新辅助化疗，但在新辅助化疗期间，患者出现阴道漏尿。随后，患者接受了包括盆腔脏器廓清术、泌尿系统重建、盆底重建和化疗在内的综合治疗方案。鉴于患者表皮生长因子受体免疫组化呈阳性，治疗中联合使用了抗血管生成药物贝伐单抗。综合治疗后患者实现完全缓解。通过该病例探讨宫颈LCNEC的个体化治疗。
